Saturday 17 October 2026 Export CLNN’s income statement to Excel — free account

Clene Inc.

Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.10 0.21 −6.34%

Follow CLNN

Alert me

Market cap: $47.0M
P/E: 0.0×
Fwd P/E: −3.1×
Dividend yield: —
F-score: 2/9
Altman Z: −27.14
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.22

Total sells 5.78

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	—	—	—	—	—	—	—	—	—
Sell	—	5	7	1	2	5	2	—	—	—	—	—

Insider Ownership 8.58%

Capital & Financial Ratios $m

Market Cap 46.98

Revenue 0.20

Net Income (39.52)

Free Cash Flow (15.95)

Net Debt 8.64

Current Ratio 3.07

Debt/Equity (0.74)

P/E ratio 0.00

Fwd P/E (3.05)

P/S ratio 194.86

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 2.87%

Next Y EPS Growth 41.88%

Next Y revenue growth (81.33%)

Next 5Y EPS Growth 65.56%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 48.18%

10-year low 10-year high

EV/Sales against its own 10 years 55.05%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	35	12	5	10
Receivables	0	0	—	0
Inventory	0	0	0	0
Other	—	—	—	—
	39	16	9	15

	2023	2024	2025	Q'26
Payables	2	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	25	10	11	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	(0.59%)	(24.94%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Sep	Dec	Year
’26	—	—	—
’25	0	0	0
’24	0	0	0
’23	0	0	1
’22	0	0	0
’21	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(5)	(5)	(4)	(5)	(19)
’24	(7)	(6)	(3)	(5)	(21)
’23	(9)	(7)	(7)	(7)	(30)
’22	(13)	(10)	(8)	(8)	(39)
’21	(9)	(9)	(7)	(10)	(35)
’20	(3)	(2)	(8)	(6)	(19)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(5)	(5)	(4)	(5)	(19)
’24	(7)	(6)	(3)	(5)	(21)
’23	(9)	(7)	(7)	(7)	(31)
’22	(14)	(11)	(10)	(9)	(44)
’22	—	—	—	—	(39)
’21	(9)	(9)	(8)	(10)	(36)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.69)	(1.08)	—	—	—
’25	(0.09)	(0.78)	(0.85)	(0.88)	(2.65)
’24	(1.80)	(1.06)	(1.22)	(1.67)	(5.67)
’23	(3.00)	(5.80)	(0.40)	(1.20)	(9.40)
’22	(4.20)	(1.40)	(3.40)	0.00	(9.20)
’21	(13.20)	(1.00)	8.40	1.40	(3.20)
’20	(4.54)	(6.70)	(11.86)	1.08	(22.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	193.00	198.00	206.00	75.60	17.40	5.00	3.82	2.28	Analyst estimates 2026–2028 Powerpack
	High	—	—	199.00	210.00	350.00	356.40	102.60	39.80	11.00	13.50
People
People	Employees	—	—	—	—	74	102	86	85	76	79
	Revenue/emp, $m	—	—	—	—	0.00	0.01	0.01	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	0	1	0	1	0	0
	Gross margin, %	—	—	—	0.00	68.45	60.03	94.50	81.50	79.53	78.50
	EBT	—	0	0	(16)	(19)	(10)	(30)	(50)	(39)	(26)
	EBT margin, %	—	0.00	0.00	0.00	(9,160.68)	(1,406.36)	(6,325.16)	(7,569.42)	(11,520.47)	(13,086.50)
	Net income	—	0	0	(16)	(19)	(10)	(30)	(50)	(39)	(26)
	Depreciation	—	0	—	1	1	1	1	2	2	1
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.24	0.23	0.15	0.12	0.05	0.02
	Earnings	—	0.00	(4.00)	(18.61)	(22.00)	(3.20)	(9.20)	(9.40)	(5.67)	(2.65)
	Cash flow	—	0.00	(3.02)	(15.21)	(21.63)	(11.25)	(11.97)	(5.75)	(3.07)	(1.88)
	Capex	—	0.00	0.00	(0.34)	(0.44)	(0.43)	(1.59)	(0.06)	0.00	0.00
	Free cash flow	—	0.00	(3.02)	(15.54)	(22.07)	(11.68)	(13.55)	(5.81)	(3.07)	(1.89)
	Book value	—	0.00	73.64	(78.09)	0.39	4.09	0.99	2.55	(1.27)	(1.78)
	Shares, m	—	2	0	1	1	3	3	5	7	10
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	919.38	349.08	130.96	46.53	107.97	289.36
	P/B	—	—	—	—	555.41	20.04	19.14	2.27	0.00	0.00
	EV/Sales	—	—	—	—	642.10	306.06	122.45	11.45	117.53	331.12
	EV/FCF	—	—	—	—	(6.85)	(6.15)	(1.31)	(0.25)	(1.88)	(3.56)
Cash, $m
Cash, $m	Operating cash flow	—	0	0	(13)	(19)	(35)	(39)	(30)	(21)	(19)
	Capex	—	0	—	0	0	(1)	(5)	0	0	0
	Free cash flow	—	0	0	(13)	(19)	(36)	(44)	(31)	(21)	(19)
Balance, $m
Balance, $m	Working capital	—	0	1	5	51	49	15	14	6	(2)
	Total debt	—	—	—	1	2	19	19	12	15	14
	Net debt	—	—	(1)	(8)	(57)	(31)	(4)	(23)	3	8
	Shareholders’ equity	—	0	5	(68)	0	13	3	13	(9)	(18)
Returns, %
Returns, %	ROA	—	0.00	(1.17)	(52.08)	(46.38)	(14.84)	(55.63)	(102.25)	(98.90)	(115.13)
	ROIC	—	0.00	(4.76)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	0.00	(11.10)	51.47	57.17	(150.56)	(377.90)	(595.47)	(1,738.36)	197.91

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HOWL Werewolf Therapeutics, Inc.	$48.5M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
ELTX Elicio Therapeutics, Inc.	$48.2M	— (loss-making)	— (loss-making)	−55.27% (below 0%: shrinking)	n/m	+8.77% (above 0%: growing)	0.00%	0.00%	Compare
ACET Adicet Bio, Inc.	$48.1M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$47.6M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)
TVGN Tevogen Inc.	$46.1M	— (loss-making)	—	—	n/m	+5.78% (above 0%: growing)	—	0.00%	Compare
INMB INmune Bio, Inc.	$45.8M	— (loss-making)	— (loss-making)	+8.70% (above 0%: growing)	n/m	+55.39% (above 0%: growing)	100.00%	0.00%	Compare
IMA ImageneBio, Inc.	$45.7M	— (loss-making)	— (loss-making)	−60.08% (below 0%: shrinking)	n/m	+23.76% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$47.7M	—	—	+54.35%	—	+17.84%	100.00%	0.00%

All 614 Biotechnology stocks →

Clene Inc. (CLNN) key facts

Concern: Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024.
Clene Inc. (CLNN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CLNN traded at $3.10, a market capitalization of $47.0 million.
Return on equity was 197.9% and debt-to-equity -0.74.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −27.14 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.